Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 15 (IL15) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 15 (IL15) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 15 (IL15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15) - The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 15 (IL15) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 15 (IL15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 15 (IL15) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Interleukin 15 (IL15) Overview 6 Therapeutics Development 7 Interleukin 15 (IL15) - Products under Development by Stage of Development 7 Interleukin 15 (IL15) - Products under Development by Therapy Area 8 Interleukin 15 (IL15) - Products under Development by Indication 9 Interleukin 15 (IL15) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Interleukin 15 (IL15) - Products under Development by Companies 12 Interleukin 15 (IL15) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Interleukin 15 (IL15) - Companies Involved in Therapeutics Development 21 Amgen Inc 21 ARMO Biosciences Inc 22 Calypso Biotech SA 23 Novartis AG 24 ZIOPHARM Oncology Inc 25 Interleukin 15 (IL15) - Drug Profiles 26 AM-0015 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 AMG-714 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 ASN-006 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BNZ-1 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BNZ-2 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CALY-002 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Cellular Immunotherapy for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 NIZ-985 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Interleukin 15 (IL15) - Dormant Projects 35 Interleukin 15 (IL15) - Discontinued Products 36 Interleukin 15 (IL15) - Featured News & Press Releases 37 May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 37 Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 37 Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 38 Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 39 Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy 39 Dec 15, 2006: Genmab Announces AMG 714 Development Update 40 May 16, 2006: AMG 714 Data To Be Presented At Eular Conference 40 Mar 10, 2006: Genmab Announces Update On AMG 714 Program With Amgen 40 Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data 41 Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15 41 Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis 41 Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis 42 Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Amgen Inc, H2 2016 21 Pipeline by ARMO Biosciences Inc, H2 2016 22 Pipeline by Calypso Biotech SA, H2 2016 23 Pipeline by Novartis AG, H2 2016 24 Pipeline by ZIOPHARM Oncology Inc, H2 2016 25 Dormant Projects, H2 2016 35 Discontinued Products, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.